ChAdOx1

ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies for HIV Cure

Retrieved on: 
Friday, April 19, 2024
Infection, ChAdOx1, HIV/AIDS, University, Bangladesh Technical Education Board, Cell, Gilead Sciences, Safety, CD4, Tissue, University of Pittsburgh, UNC, UM1, ACTG, Hook effect, Vesatolimod, Research, Toll-like receptor 7, Vaccine, University of Oxford, MVA, NIAID, University of North Carolina, Viral load, TLR7, Diagnosis, HIV, Immune system, Ageing

A5374 (Triple Immune Strategy for HIV Remission) is a multi-site, randomized, placebo-controlled trial.

Key Points: 
  • A5374 (Triple Immune Strategy for HIV Remission) is a multi-site, randomized, placebo-controlled trial.
  • After enrollment, participants will continue taking their HIV medications and will either receive a series of novel treatments or placebo.
  • Carefully monitored analytic treatment interruptions are an important part of HIV cure clinical trials.
  • ACTG is led by Dr. Currier and Joseph J. Eron, M.D., UNC (ACTG Vice-Chair).

New partnership aims to advance vaccine against MERS coronavirus

Retrieved on: 
Thursday, December 21, 2023
Epidemic, Partnership, Immune system, University of Oxford, Infection, PRIME, EMA, Urinary tract infection, Barinthus, WHO, Oxford–AstraZeneca COVID-19 vaccine, Vaccine, MERS, MERS-related coronavirus, CEPI, Vaccination, Coalition, Clinical trial, Cancer, University, ChAdOx1, COVID-19, European Medicines Agency, Policy, Public, Coronavirus, Phase II, Medicine, Public health, Autoimmunity, Pharmaceutical industry

“We had a head-start in our development of the Oxford/AstraZeneca COVID-19 vaccine, thanks to the many years already spent researching a vaccine for another coronavirus, MERS.

Key Points: 
  • “We had a head-start in our development of the Oxford/AstraZeneca COVID-19 vaccine, thanks to the many years already spent researching a vaccine for another coronavirus, MERS.
  • “There is an active need for a MERS vaccine for at-risk populations and travellers in the Middle East.
  • MERS is a severe respiratory infection caused by MERS-CoV, a coronavirus that was first identified in 2012 in Saudi Arabia.
  • The vaccine will be made available to low- and middle-income countries at a price no higher than the cost of manufacturing plus 10 percent.

Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

Retrieved on: 
Tuesday, October 10, 2023
COVID-19, NIAID, Nextgen, Vaccine, Public, ChAdOx1, Therapy, Project, Inhalation, Infection, National Institute of Allergy and Infectious Diseases, Vaccination, Bangladesh Technical Education Board, BARDA, Pharmaceutical industry

Ocugen is developing a novel anti-viral mucosal vaccine platform initially targeting COVID-19 and influenza (flu).

Key Points: 
  • Ocugen is developing a novel anti-viral mucosal vaccine platform initially targeting COVID-19 and influenza (flu).
  • NIAID, with funding from Project NextGen, will cover the full cost of the clinical trials, including operations and related analysis.
  • Ocugen will be responsible for providing clinical trial materials and upon completion will have full right of reference to the findings, which Ocugen believes will provide clinical evidence to support the further development of the Company’s lead mucosal vaccine candidate.
  • Ocugen looks forward to this important next step in the development of its novel mucosal vaccine platform and further supporting the Company’s commitment to advancing public health.

Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, May 11, 2023
KRAS, SIV, Coalition, National Institute of Allergy and Infectious Diseases, Survival, RECIST, Congress, Lance, Patient, SLATE, Collaboration, Infection, Vaccination, Gritstone bio, National Cancer Institute, Research, Melinda French Gates, Lung cancer, ECCMID, Bill, CORAL, Conference, Vaccine, DNA, Gilead Sciences, Simian immunodeficiency virus, ESMO, CEPI, African, NSCLC, NAB, Immunotherapy, Messenger, CROI, Bill & Melinda Gates Foundation, European, NIAID, Epidemic, Circulating tumor DNA, CRC, HIV, Progression-free survival, SARS-CoV-2, Clinical trial, Coalition for Epidemic Preparedness Innovations, ChAdOx1, Fungal infection, Cryptocurrency, Pharmaceutical industry, Gritstone

EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate and clinical updates.

Key Points: 
  • We recently observed durable neutralizing antibody titers at 6 months following samRNA vaccination in over 100 vaccine-naïve subjects treated within our CORAL-CEPI trial, where interim results were presented at ECCMID 2023.
  • As of May 10, 2023, the company had randomized 71 of the initially planned 80 total patients.
  • Both datasets were presented at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023).
  • In February 2023, results from a preclinical study conducted in collaboration with Gilead were presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2023.

Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, March 9, 2023
SIV, Vaccine, Cancer, HIV, Neoplasm, Trifluridine/tipiracil, United States Patent and Trademark Office, MOS, Clinical trial, NCI, 1836 U.S. Patent Office fire, KRAS, ESMO, Fungal infection, Infection, CRC, National Cancer Institute, Simian immunodeficiency virus, Conference, Collaboration, CROI, Research, NIAID, Patient, FDA, DNA, Circulating tumor DNA, RECIST, Patent, Gilead Sciences, OS, MRR, Regorafenib, Progression-free survival, Therapy, ChAdOx1, NSCLC, Messenger, Immunotherapy, CORAL, SLATE, Pharmaceutical industry, Cryptocurrency, Nature Medicine, Gritstone

-- Gritstone to host conference call today at 4:30pm ET --

Key Points: 
  • -- In August 2022, interim results from the Phase 1/2 trial of GRANITE, Gritstone’s individualized neoantigen vaccine for solid tumor cancers, were published in Nature Medicine ( here ).
  • -- In August 2022, Gritstone reported 6-month neutralizing antibody data from the first two cohorts of its CORAL-BOOST trial.
  • -- In October 2022, Gritstone shared interim positive results from the ongoing Phase 1 CORAL-BOOST and CORAL-CEPI studies at a Company-sponsored webinar .
  • Collaboration, license, and grant revenues were $19.9 million for the year ended December 31, 2022, compared to $48.2 million for the prior year.

Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies

Retrieved on: 
Tuesday, February 21, 2023
Research, Infectious Diseases, Hospitals, FDA, Clinical Trials, Biotechnology, AIDS, Pharmaceutical, Health, Science, University of California, San Francisco, HIV/AIDS research, HIV, University, MD, TITAN, Simian immunodeficiency virus, Fungal infection, Infection, ART, SIV, Gilead Sciences, ChAdOx1, Hook effect, Conference, Canadian Foundation for AIDS Research, Aarhus University, Vaccine, CROI, Pharmaceutical industry

These latest findings represent an ongoing multi-pronged approach in Gilead’s HIV cure research program.

Key Points: 
  • These latest findings represent an ongoing multi-pronged approach in Gilead’s HIV cure research program.
  • Findings from the HIV cure research program include results from three studies evaluating strategies to maintain virologic control in the absence of ART.
  • “Gilead will continue exploring novel combination strategies in our pursuit to help end the HIV epidemic for everyone, everywhere.”
    Curing HIV remains the ultimate aspiration of Gilead’s HIV research and development efforts.
  • Gilead has a comprehensive cure research and development program that is advancing with speed and conviction.

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, November 10, 2022
AstraZeneca, Private Securities Litigation Reform Act, IV, IND, Nivolumab, Vaccine, U.S. Securities and Exchange Commission, ChAdOx1, MVA, Tumor microenvironment, Research, AASLD, HPV, G&A, Șaeș, SEC, Annual report, Degenerative disease, University, Vaccitech, Company, Vaccination, Cancer, Asian Liver Center, CHB, Clinical trial, OUI, Patient, Immune system, Autoimmunity, Ulsan College, Drug discovery, Security (finance), Insurance, COVID-19, Pharmaceutical industry, Food delivery, HBsAg, Gastroenterology, Cell

An Investigational New Drug (IND) application submission is expected during the first half of 2023 for HPV related cancer.

Key Points: 
  • An Investigational New Drug (IND) application submission is expected during the first half of 2023 for HPV related cancer.
  • On September 20, 2022, we announced the promotion of Gemma Brown to Chief Financial Officer.
  • Vaccitech is entitled to receive a share of all milestone and royalty income received by OUI from AstraZeneca related to Vaxzevria.
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Vaccitech to Present at Upcoming November Investors Conferences

Retrieved on: 
Wednesday, November 9, 2022
ChAdOx1, Oxford University Innovation, AstraZeneca, OUI, University, Immune system, Autoimmunity, Company, Cancer, MVA, COVID-19, Vaccine, Vaccitech

Vaccitech will also participate in 1x1 investor meetings at the conferences.

Key Points: 
  • Vaccitech will also participate in 1x1 investor meetings at the conferences.
  • Meetings can be booked directly with the Company or with the relevant bank representatives.
  • Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI.
  • Vaccitech is entitled to receive a share of all milestones and royalty income received by OUI from AstraZeneca.

Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300

Retrieved on: 
Wednesday, November 2, 2022
Liver, ChAdOx1, University, Antigen, Liver disease, Vaccitech, Cancer, Oxford University Innovation, COVID-19, Autoimmunity, Immunotherapy, HBV, Immune system, Safety, Nivolumab, MVA, OUI, AstraZeneca, AASLD, Vaccine, D.C

Study of Liver Disease (AASLD) - The Liver Meeting, Washington, D.C.

Key Points: 
  • Study of Liver Disease (AASLD) - The Liver Meeting, Washington, D.C.
    VTP-300 is a novel immunotherapy, dosed in a prime-boost regimen, whereby the immune system is primed with an adenovirus (ChAdOx) and boosted with a pox virus (MVA).
  • Both vectors have been modified to improve safety, enhance the immune response they induce and include HBV specific antigens including core, polymerase and surface antigen.
  • Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI.
  • Vaccitech is entitled to receive a share of all milestones and royalty income received by OUI from AstraZeneca.

Vaccitech Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 immunotherapeutic candidate for Chronic HBV Patients

Retrieved on: 
Monday, October 31, 2022
U.S. Securities and Exchange Commission, Safety, Queen Mary Hospital (Hong Kong), University, Annual report, HBV, University of Hong Kong, ChAdOx1, Private Securities Litigation Reform Act, Patient, OUI, SEC, Cancer, Oxford University Innovation, Immune system, Company, Security (finance), GLOBE, NASDAQ, Population, Autoimmunity, Vaccine, COVID-19, Queen, AstraZeneca, MVA, Hospital, HBsAg, Pharmaceutical industry, Vaccitech

HBV003 is a Phase 2b clinical trial designed to further evaluate the safety and efficacy of VTP-300 when combined with a low-dose anti-PD-1 antibody in patients with chronic hepatitis B infection.

Key Points: 
  • HBV003 is a Phase 2b clinical trial designed to further evaluate the safety and efficacy of VTP-300 when combined with a low-dose anti-PD-1 antibody in patients with chronic hepatitis B infection.
  • VTP-300 includes Vaccitechs prime-boost platform, which utilizes 2 nonreplicating viral vectors, ChAdOx1 and MVA.
  • Each viral vector encodes HBV antigens to elicit an immune response against HBV.
  • We have been very encouraged by data emerging from our open-label HBV002 study, which shows that VTP-300 induced significant and sustained HBsAg declines in some patients with chronic HBV.